Alteon misses Phase IIb endpoint

ALT said its ALT-711 advanced glycosylation endproduct (AGE) cross-link breaker failed to significantly lower systolic hypertension compared to placebo in two Phase IIb trials. The double-blind, U.S. SAPPHIRE and SILVER

Read the full 308 word article

How to gain access

Continue reading with a
two-week free trial.